simoctocog alfa: clinical use

Prescribing considerations

• Initiate and supervise treatment through clinicians experienced in haemophilia care.
• Assess clinical haemostasis and factor VIII recovery, as individual response varies.
• Plan replacement and laboratory monitoring carefully for surgery.
• Record the product name and batch number for each administration.
• Consider cardiovascular risk and complications associated with central venous access devices.

Contraindications and cautions

• Hypersensitivity to simoctocog alfa or any formulation excipient.
• Use caution where there is a previous factor VIII inhibitor, inadequate clinical response, cardiovascular risk or a central venous access device.

Monitoring

• Clinical control of bleeding and factor VIII activity.
• Factor VIII inhibitors when response is inadequate, bleeding persists or after switching products, particularly in patients with previous inhibitors.
• Interpret one-stage clotting assay results with awareness of reagent and reference-standard variability; chromogenic and one-stage results may differ.
• Central venous access sites for infection, bacteraemia and thrombosis where applicable.

Clinical pharmacology

A B-domain-deleted recombinant human factor VIII produced in genetically modified human HEK 293F cells. It binds circulating von Willebrand factor and restores factor VIII cofactor activity in the intrinsic coagulation pathway.

Formulation and product differences

• The selected presentation is a powder vial supplied with a pre-filled syringe of water for injections, vial adapter, butterfly needle and alcohol swabs.
• After reconstitution, the solution should be clear and colourless and must not be used if cloudy or containing deposits.
• The formulation contains sodium and should not be mixed with other medicinal products.
• No animal-derived or human-derived materials are added during manufacture or to the finished product.

Injection

Route: Parenteral

Strengths: 250 units, 500 units, 1000 units, 1500 units, 2000 units